Eyepoint Pharmaceuticals (EYPT) Expected to Announce Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.92) per share and revenue of $0.3870 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.35 million. On average, analysts expect Eyepoint Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Eyepoint Pharmaceuticals Trading Down 3.6%

NASDAQ EYPT opened at $11.96 on Wednesday. The company has a fifty day simple moving average of $13.20 and a 200 day simple moving average of $13.96. Eyepoint Pharmaceuticals has a 12-month low of $9.40 and a 12-month high of $19.11. The company has a market cap of $1.00 billion, a P/E ratio of -3.42 and a beta of 1.73.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of EYPT. California State Teachers Retirement System lifted its stake in Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after acquiring an additional 794 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after acquiring an additional 1,177 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Eyepoint Pharmaceuticals by 5.2% in the 4th quarter. MetLife Investment Management LLC now owns 41,799 shares of the company’s stock worth $764,000 after acquiring an additional 2,081 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Eyepoint Pharmaceuticals by 13.5% in the fourth quarter. The Manufacturers Life Insurance Company now owns 22,775 shares of the company’s stock valued at $416,000 after purchasing an additional 2,711 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in shares of Eyepoint Pharmaceuticals by 20.8% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 20,073 shares of the company’s stock valued at $367,000 after purchasing an additional 3,459 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EYPT has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. Chardan Capital lifted their price objective on shares of Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Royal Bank Of Canada lowered their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Stifel Nicolaus began coverage on shares of Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Guggenheim reaffirmed a “buy” rating and issued a $68.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eyepoint Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.75.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.